Drug Profile
Parentide - DiverDrugs
Alternative Names: DD 04107Latest Information Update: 04 Oct 2023
Price :
$50
*
At a glance
- Originator DiverDrugs
- Developer BCN Peptides; DiverDrugs
- Class Antipruritics; Non-opioid analgesics; Peptides
- Mechanism of Action TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Pruritus
- Discontinued Cancer pain; Neuropathic pain
Most Recent Events
- 21 Oct 2022 BCN Peptides completes a phase II/III trial in Pruritus (In volunteers) in Spain (Topical) (EudraCT2022-001374-60)
- 12 May 2022 Phase-II/III clinical trials in Pruritus (In volunteers) in Spain (Topical) (EudraCT2022-001374-60)
- 10 Apr 2017 Phase-II clinical trials in Neuropathic pain in Spain (SC)